Samrotamab, also known as LCL100, represents a exciting breakthrough in cancer research. This novel clonal protein is currently in progress trials and demonstrates impressive promise for combating various cancers, https://socialmediainuk.com/story26672710/samrotamab-a-potential-targeted-antibody-in-testing